Anthem is launching an in-house PBM, IngenioRx, in Q2, earlier than expected. The health insurer previously worked with Express Scripts, but is terminating the contract after its acquisition of Cigna last year. (Forbes)

The divided Congress seems to agree on one thing: tackling high drug prices. Committees in both the House and Senate held hearings on drug prices on Tuesday. Both heard testimony from parents struggling to pay for their children’s insulin and on experts’ proposals to reduce drug costs and reform the rebate system. (STAT)

Sen. Patty Murray (D-WA) has requested documents related to talc products from Johnson & Johnson. In her letter, Murray asked for information about the testing of J&J’s talc products for carcinogens and “how it presented that information to regulators and consumers.” (Reuters)

An Israeli biotech has claimed it developed a cure for cancer. The company, Accelerated Evolution Biotechnologies, said it could have the cure ready in one year, but has only done research on mice, in which the drug targeted and killed cancer cells. (CNBC)

Roche will halt its late-stage Alzheimer’s trials. An early analysis indicated the trial would not meet its goal for the drug Roche is developing with AC Immune. It is the latest failure for an Alzheimer’s drug in recent years, after efforts from Eli Lilly, Pfizer, Bayer, and GlaxoSmithKline. (Reuters)